Liège, Belgium and Gothenburg, Sweden – October 15, 2024: AARDEX Group, a leader in managing drug exposure in clinical trials, and precision medicine innovators, and OnDosis, a game changer in precision dosing of oral solid medicines through the novel Dosage … Read More
Company News
One size fails all? The weight of evidence for personalized dosing in oral GLP-1 therapies
The Rise of GLP-1 Therapies In recent years, the pharmaceutical industry has borne witness to the meteoric rise of glucagon-like peptide-1 receptor agonist (GLP-1) therapies. Having fast become established as a potentially life-changing treatment for Type 2 diabetes and obesity, emerging … Read More
AARDEX Group and Compliance Meds Technologies sign collaboration agreement
AARDEX Group, the global leader in medication adherence solutions, has today announced a collaboration agreement with Compliance Meds Technologies (CMT), a mobile-health technology solutions provider. AARDEX MEMS® Adherence Software with Compliance Meds Technologies CleverCap® In this cooperation, the partners will … Read More
Innovative Approaches to Enhance and Measure Medication Adherence in Chronic Disease Management
Medication adherence is a vital component in managing chronic diseases effectively. However, it remains a significant challenge, with non-adherence rates reaching up to 50% among patients. This lack of adherence results in poor health outcomes and increased burdens on healthcare … Read More
Is the data from randomised clinical trials (RCT) random to the point of pointless?
In a recent paper titled ‘The impacts of undetected nonadherence in phase II, III and post-marketing clinical trials: An overview’ the authors detailed the findings of a research project which aimed to provide an overview of the consequences of unrecognized … Read More
AARDEX Group and SHL Medical forge strategic alliance to interface medication adherence software with connected self-injection solutions
AARDEX Group Belgium – SHL Medical, a world-leading provider of drug delivery devices, and AARDEX Group, the global leader in medication adherence solutions, today announced their strategic partnership aimed at delivering an end-to-end solution for pharma customers seeking to demonstrate … Read More
Challenging the Status Quo for Measuring Medication Adherence in Clinical Trials
Poor adherence to the investigational product can bring even the most carefully planned clinical trial to its knees. It is time to accept that traditional approaches such a pill count do not work. We need to upset the status quo … Read More
AARDEX Group and medmix Join Forces to Improve Self-Administration of Injectable Drugs in Clinical Trials
Belgium – medmix Drug Delivery (Haselmeier) and AARDEX Group announced today a collaboration, combining Haselmeier´s D-Flex™ Logbook with AARDEX Group’s Medication Adherence software and hardware ecosystem. Clinical testing during new drug development is costly and time intensive for pharmaceutical and … Read More
Clinical Trials Europe 2022: Learn About Unlocking Medication Adherence Insights to Enhance Drug Development
Poor medication adherence in clinical trials may be a long-standing challenge, but advanced approaches and technologies are finally cutting it down to size. Join AARDEX’s scientific lead at the 21st Clinical Trials Europe event to find out how. Bernard Vrijens and … Read More
Therapeutic Drug Monitoring: The Difference Between Accurate and Reliable
Adherence to medication during clinical trials is a problem of striking magnitude, and one that researchers have employed therapeutic drug monitoring (TDM) to solve for years. But the approach, which measures the level drug or drug metabolites in patients’ blood, … Read More